Pfizer releases hemophilia B PhIII data in challenge to CSL's Hemgenix
Pfizer’s hemophilia B gene therapy showed strong results in a Phase III trial, sharply reducing the rate of bleeding in patients and drastically cutting their …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.